NKTR Drug delivery Company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company

NKTR 55.97

+1.5%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (416)

10/1/2018 5:52:57 PM

From: Miljenko Zuanic

Read Replies (2) of 507

From SITC:

P424

NKTR-214, an engineered IL-2, selectively depletes intratumoral Tregs and expands immunotherapy-induced effector T cell responses

Meenu Sharma1; Salah Eddine Bentebibel; Cara Haymaker2; Hiep Khong3; Faisal Fa'ak4; Brent C. Chesson; Barbara M. Pazdrak; Laura Maria S Kahn; Louise Janssen5; Uddalak Bharadwaj; Binisha Karki; Zhilan Xiao6; Yared Hailemichael7; Manisha Singh8; Christina Vianden9; David Tweardy; Chantale Bernatchez; Adi Diab10; Ute Hoch11; Jonathan Zalevsky12; Willem W. Overwijk13

1MD Anderson Cancer Center; 2University of Texas MD Anderson Cancer Center; 3University of Texas- MD Anderson Cancer; 4MD Anderson Cancer center; 5UT MD Anderson Cancer Center; 6University of Texas; 7The University of Texas MD Anderson Canc; 8University of Texas MD Anderson Cancer C; 9University of Texas MD Anderson Cancer C; 10University of Texas MD Anderson Cancer C; 11Nektar; 12Nektar Therapeutics; 13University of Texas MD Anderson Cancer C

This must be (????) from humans subject's tumor samples (biopsy),.... so....

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next